NexPlasmaGen's new funding for R&D and commercialization | NexPlasmaGen
post-template-default,single,single-post,postid-17180,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.0,vc_responsive

NexPlasmaGen’s new funding for R&D and commercialization

NexPlasmaGen’s new funding for R&D and commercialization

Montreal / October 06, 2023 – NexPlasmaGen received a financial support of $219,500 from Quebec’s Ministère de l’économie, de l’innovation et de l’énergie (MEIE), the National Research Council of Canada (NRC), the Université de Montréal (UdM) and the Mouvement des accélérateurs d’innovation du Québec (MAIN) to support clinical trials at the CHUM for the treatment of breast cancer, the design of its medical device and prepare for commercialization.

The funding comes from the programs of MEIE’s ADOPT volet II and Aide à l’entrepreneuriat Volet 3 – Soutien aux entreprises technologiques innovantes, Université de Montréal’s Partenariat-UdM, RNC’s IRAP, and Momentum MAIN.

“This MEIE, NRC, UdM and MAIN financial support will enable us to advance the development of our medical device and to start its commercialization,” said Dr. Valérie Léveillé, CEO of NexPlasmaGen.


NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.


Valérie Léveillé, CEO/Founder


No Comments

Post A Comment